Gyre Therapeutics (GYRE) Restructuring Costs (2012 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Restructuring Costs of $874000.0 for Q2 2015, down 24.39% quarter-over-quarter from $1.2 million in Q1 2015.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Restructuring Costs (2012 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Restructuring Costs for 3 consecutive years, with $874000.0 the latest figure, recorded in Q2 2015.
- In Q2 2015, Restructuring Costs changed N/A year-over-year to $874000.0; the TTM figure through Jun 2015 stood at $3.8 million (changed N/A YoY), while the FY2014 annual figure was $318000.0, up 3.92% from the prior year.
- Restructuring Costs retreated to $874000.0 in Q2 2015 per GYRE's latest filing, from $1.2 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $2.3 million in Q2 2012 and bottomed at $318000.0 in Q4 2014.
- Historically, Restructuring Costs has averaged $1.2 million across 3 years, with a median of $1.2 million in 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2015 | 874,000.00 |
| Mar 31, 2015 | 1.16 Mn |
| Dec 31, 2014 | 318,000.00 |
| Dec 31, 2012 | 1.41 Mn |
| Jun 30, 2012 | 2.31 Mn |